DAIICHI SANKYO, INC.

The Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding US$ 10 Billion in 2023. The market is projected to reach over US$ 50 Billion by 2030, driven by ongoing clinical trials and increasing R&D efforts. Key players include Enhertu, Kadcyla, and Padcev, with significant development activity focused on lung and breast cancers.

Merck's Q3 revenue and adjusted earnings exceeded expectations, driven by strong sales of Keytruda, new treatments, and animal health products. However, Gardasil sales fell 11%, missing forecasts. The company narrowed its full-year sales forecast and lowered adjusted profit guidance, reflecting a one-time charge. Merck's pharmaceutical division revenue rose 5%, with Keytruda sales up 17%. Despite challenges, Merck anticipates significant drug launches over the next five years.

Daiichi Sankyo and AstraZeneca launch three Phase III trials to assess datopotamab deruxtecan (Dato-DXd) combinations in advanced nonsquamous NSCLC, involving rilvegostomig, osimertinib, and chemotherapy.

Datopotamab deruxtecan, a TROP2-directed ADC developed by Daiichi Sankyo and AstraZeneca, is being tested in three phase 3 trials for nonsquamous non-small cell lung cancer. The trials aim to evaluate its efficacy in combination with targeted treatments or immunotherapies, with primary endpoints focusing on progression-free survival and overall survival.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

Three phase 3 trials initiated for datopotamab deruxtecan-based combinations in advanced nonsquamous non-small cell lung cancer patients, evaluating efficacy and safety.

American Regent launches 30 mL Epinephrine Injection, USP for treating anaphylaxis and hypotension in septic shock. Available for immediate shipment, it is supplied as a 30 mL multiple-dose vial (1 mg/mL).

The global MoCoD-A treatment market, valued at USD 25 million in 2022, is projected to reach USD 89.96 million by 2033, driven by advancements in genetic and precision medicine. Key players include BridgeBio Pharma, Origin Biosciences, and Orphatech Pharmaceuticals, with treatments like BBP-871 for MoCoD-A. The market growth emphasizes the need for continued research in rare genetic diseases.

DelveInsight's 'Duchenne Muscular Dystrophy (DMD) Pipeline Insight, 2024' analyzes over 75 pipeline drugs from 75+ companies, focusing on recent FDA, EMA, and PMDA approvals, clinical trials, emerging therapies, and key players like Roche, Santhera, and Sarepta. The report covers various stages of development, routes of administration, and mechanisms of action, offering insights into the evolving DMD therapeutics landscape.